The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.
C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.
Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.
Asaf and Omri’s conversation begins at 11:15
Visit C2i to learn more – https://c2i-genomics.com/
As Founders ourselves, we respect your time. That’s why we built BriefLink, a new software tool that minimizes the upfront time of getting the VC meeting.
Simply tell us about your company in 9 easy questions, and you’ll hear from us if it’s a fit.Tell Omri Amirav-Drory, Ph.D. about your company